Etrolizumab in UC: Etrolizumab/placebo for anti-TNF naive patients

Print

Details of Research

Contact: Shelley Mikolainis, Research Coordinator
416-586-4800 ext 4989
smikolainis@mtsinai.on.ca

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Expectation: Open label for 10 weeks then responders will go into a blinded Maintenance phase, open label extension study possible at week 62 or after week 10 for nonresponders

Eligibility


Exclusions
: strictures, prior tx with anti-integrin agents (vedolizumab)